Susanna Cheng

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +15

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 648 citations · Full text

Medicine, Oncology, Pharmacology +11

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

Impact of Reflex <i>EGFR</i>/<i>ALK</i> Testing on Time to Treatment of Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer

Parneet Cheema, Ines B. Menjak, Zoe Winterton-Perks et al. · Journal of Oncology Practice · 2017 · 59 citations · Full text

Medicine, Oncology, Medical Oncology +10

Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients

Petra Martin, Carolyn J Shiau, Maria Pasic et al. · British Journal of Cancer · 2016 · 18 citations · Full text

Medicine, Oncology, Pathology +17